Bausch Health’ acne lotion included in drug plans of four Canadian provinces

Bausch Health’s new topical prescription treatment for acne vulgaris, Arazlo, is now available to patients through the provincial public drug plans of Quebec, Ontario, Alberta and Saskatchewan, as well as the federal government’s Non-Insured Health Benefits drug plan, which serves Canada’s First Nations and Inuit populations. Arazlo is the first tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older. The listings by the four public drug plans are the first for Arazlo in Canada, with others expected to follow as a result of the successful conclusion of listing negotiations with the pan-Canadian Pharmaceutical Alliance.